Financhill
Buy
61

AMRX Quote, Financials, Valuation and Earnings

Last price:
$8.63
Seasonality move :
13.22%
Day range:
$8.60 - $8.84
52-week range:
$5.18 - $9.48
Dividend yield:
0%
P/E ratio:
101.17x
P/S ratio:
0.96x
P/B ratio:
5.62x
Volume:
1.6M
Avg. volume:
1.7M
1-year change:
56.73%
Market cap:
$2.7B
Revenue:
$2.8B
EPS (TTM):
-$0.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AMRX
Amneal Pharmaceuticals
$708.1M $0.15 9.69% 125.42% $11.50
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
IVVD
Invivyd
$13.6M -$0.10 1529.58% -85.08% $6.67
PEPG
PepGen
-- -$0.72 -- -19.05% $12.20
STAA
Staar Surgical
$77.5M -$0.01 -47.87% -731.74% $18.67
SUPN
Supernus Pharmaceuticals
$155.3M $0.52 2.26% 16648.77% $38.80
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AMRX
Amneal Pharmaceuticals
$8.62 $11.50 $2.7B 101.17x $0.00 0% 0.96x
AMGN
Amgen
$317.17 $315.95 $170.4B 42.01x $2.38 2.88% 5.12x
IVVD
Invivyd
$0.80 $6.67 $96.3M -- $0.00 0% --
PEPG
PepGen
$2.40 $12.20 $78.3M -- $0.00 0% --
STAA
Staar Surgical
$17.07 $18.67 $842M 49.73x $0.00 0% 2.69x
SUPN
Supernus Pharmaceuticals
$31.26 $38.80 $1.7B 23.64x $0.00 0% 2.64x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AMRX
Amneal Pharmaceuticals
104.6% 0.481 101.3% 0.81x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
IVVD
Invivyd
-- -4.320 -- 1.47x
PEPG
PepGen
-- -2.752 -- --
STAA
Staar Surgical
-- 1.099 -- 4.41x
SUPN
Supernus Pharmaceuticals
-- 1.273 -- 2.04x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AMRX
Amneal Pharmaceuticals
$262.9M $54.1M -4.58% -587.3% 6.34% $95M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
IVVD
Invivyd
$8.5M -$62.3M -- -- -670.01% -$41.1M
PEPG
PepGen
-- -$24.3M -- -- -- -$19.7M
STAA
Staar Surgical
$31.6M -$27.9M -5.02% -5.02% -57.02% -$5.1M
SUPN
Supernus Pharmaceuticals
$148.1M $21.8M 7.61% 7.61% 15.15% $44.2M

Amneal Pharmaceuticals vs. Competitors

  • Which has Higher Returns AMRX or AMGN?

    Amgen has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of 6.9%. Amneal Pharmaceuticals's return on equity of -587.3% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About AMRX or AMGN?

    Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could fall by -0.39%. Given that Amneal Pharmaceuticals has higher upside potential than Amgen, analysts believe Amneal Pharmaceuticals is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMRX
    Amneal Pharmaceuticals
    1 0 0
    AMGN
    Amgen
    9 14 2
  • Is AMRX or AMGN More Risky?

    Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock AMRX or AMGN?

    Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios AMRX or AMGN?

    Amneal Pharmaceuticals quarterly revenues are $730.5M, which are smaller than Amgen quarterly revenues of $9.1B. Amneal Pharmaceuticals's net income of -$31.1M is lower than Amgen's net income of $627M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Amgen's PE ratio is 42.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus 5.12x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
    AMGN
    Amgen
    5.12x 42.01x $9.1B $627M
  • Which has Higher Returns AMRX or IVVD?

    Invivyd has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of -653.11%. Amneal Pharmaceuticals's return on equity of -587.3% beat Invivyd's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
  • What do Analysts Say About AMRX or IVVD?

    Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Invivyd has an analysts' consensus of $6.67 which suggests that it could grow by 728.47%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMRX
    Amneal Pharmaceuticals
    1 0 0
    IVVD
    Invivyd
    1 1 0
  • Is AMRX or IVVD More Risky?

    Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Invivyd has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock AMRX or IVVD?

    Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Invivyd pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMRX or IVVD?

    Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Invivyd quarterly revenues of $9.3M. Amneal Pharmaceuticals's net income of -$31.1M is higher than Invivyd's net income of -$60.7M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Invivyd's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus -- for Invivyd. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
  • Which has Higher Returns AMRX or PEPG?

    PepGen has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of --. Amneal Pharmaceuticals's return on equity of -587.3% beat PepGen's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
    PEPG
    PepGen
    -- -$0.68 --
  • What do Analysts Say About AMRX or PEPG?

    Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand PepGen has an analysts' consensus of $12.20 which suggests that it could grow by 409.4%. Given that PepGen has higher upside potential than Amneal Pharmaceuticals, analysts believe PepGen is more attractive than Amneal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMRX
    Amneal Pharmaceuticals
    1 0 0
    PEPG
    PepGen
    3 0 0
  • Is AMRX or PEPG More Risky?

    Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock AMRX or PEPG?

    Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMRX or PEPG?

    Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than PepGen quarterly revenues of --. Amneal Pharmaceuticals's net income of -$31.1M is lower than PepGen's net income of -$22.2M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
    PEPG
    PepGen
    -- -- -- -$22.2M
  • Which has Higher Returns AMRX or STAA?

    Staar Surgical has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of -69.92%. Amneal Pharmaceuticals's return on equity of -587.3% beat Staar Surgical's return on equity of -5.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
    STAA
    Staar Surgical
    64.65% -$0.69 $397.3M
  • What do Analysts Say About AMRX or STAA?

    Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Staar Surgical has an analysts' consensus of $18.67 which suggests that it could grow by 9.35%. Given that Amneal Pharmaceuticals has higher upside potential than Staar Surgical, analysts believe Amneal Pharmaceuticals is more attractive than Staar Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMRX
    Amneal Pharmaceuticals
    1 0 0
    STAA
    Staar Surgical
    3 9 1
  • Is AMRX or STAA More Risky?

    Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Staar Surgical has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.006%.

  • Which is a Better Dividend Stock AMRX or STAA?

    Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMRX or STAA?

    Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Staar Surgical quarterly revenues of $49M. Amneal Pharmaceuticals's net income of -$31.1M is higher than Staar Surgical's net income of -$34.2M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus 2.69x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
    STAA
    Staar Surgical
    2.69x 49.73x $49M -$34.2M
  • Which has Higher Returns AMRX or SUPN?

    Supernus Pharmaceuticals has a net margin of -4.26% compared to Amneal Pharmaceuticals's net margin of 8.8%. Amneal Pharmaceuticals's return on equity of -587.3% beat Supernus Pharmaceuticals's return on equity of 7.61%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
    SUPN
    Supernus Pharmaceuticals
    85.02% $0.27 $1B
  • What do Analysts Say About AMRX or SUPN?

    Amneal Pharmaceuticals has a consensus price target of $11.50, signalling upside risk potential of 33.41%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 24.12%. Given that Amneal Pharmaceuticals has higher upside potential than Supernus Pharmaceuticals, analysts believe Amneal Pharmaceuticals is more attractive than Supernus Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMRX
    Amneal Pharmaceuticals
    1 0 0
    SUPN
    Supernus Pharmaceuticals
    2 3 0
  • Is AMRX or SUPN More Risky?

    Amneal Pharmaceuticals has a beta of 1.049, which suggesting that the stock is 4.898% more volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.47%.

  • Which is a Better Dividend Stock AMRX or SUPN?

    Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMRX or SUPN?

    Amneal Pharmaceuticals quarterly revenues are $730.5M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Amneal Pharmaceuticals's net income of -$31.1M is lower than Supernus Pharmaceuticals's net income of $15.3M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Supernus Pharmaceuticals's PE ratio is 23.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.96x versus 2.64x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
    SUPN
    Supernus Pharmaceuticals
    2.64x 23.64x $174.2M $15.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock